Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Processa Pharmaceuticals, Inc.PCSA · Entity 8210 | Chief Administrative Officer | July 26, 2026 | July 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Processa Pharmaceuticals, Inc.
Report date July 26, 2026 · Filed July 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 11,669 |
Reported balance
After 2026-07-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-26 · Grant · Acquired 9,450 · Balance 11,669 F1: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death. F3: Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025. |
| Common StockSEC Table I · non-derivative | Direct | 14,394 |
Reported balance
Holding disclosure · report date 2026-07-26 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 14,394 |
| Common StockSEC Table I · non-derivative | IndirectBy CorLyst, LLC | 333 |
Reported balance
Holding disclosure · report date 2026-07-26 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 333 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.96 | Direct | 6,000 |
Reported balance
Holding disclosure · report date 2026-07-26 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 6,000 F2: Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years. F3: Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.
F2: Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years.
F3: Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 26, 2026 Filed Jul 29, 2026 00:22 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 9,450 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-26-001548 · form4.xml · derivative · entry 3 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,669 Underlying: Common Stock · 9,450 shares Expires not disclosed F1 · shares: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death. F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death. F3 · balance_after: Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:20 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 2,436 | $1.93 | $4,701.48 |
DisclosureSEC source: 0000897069-26-001484 · form4.xml · nonDerivative · entry 1 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,394 Read SEC document |
| June 15, 2026 Filed Jun 16, 2026 20:20 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 2,118 | $2.22 | $4,701.96 |
DisclosureSEC source: 0000897069-26-001406 · form4.xml · nonDerivative · entry 1 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,958 Read SEC document |
| May 29, 2026 Filed Jun 1, 2026 20:55 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 1,829 | $2.57 | $4,700.53 |
DisclosureSEC source: 0000897069-26-001287 · form4.xml · nonDerivative · entry 1 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,840 Read SEC document |
| May 15, 2026 Filed May 19, 2026 21:37 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 1,583 | $2.97 | $4,701.51 |
DisclosureSEC source: 0000897069-26-001176 · form4.xml · nonDerivative · entry 1 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,011 F1 · balance_after: Shares adjusted to correct immaterial errors made on the Form 4 filed on May 1, 2026. The corrected price per share for the purchase made on April 30, 2026 is $2.71, not $2.69, which reduces the amount purchased on April 30, 2026 by 13 shares. Read SEC document |
| April 30, 2026 Filed May 1, 2026 20:35 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 1,748 | $2.69 | $4,702.12 |
DisclosureSEC source: 0000897069-26-001002 · form4.xml · nonDerivative · entry 1 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,441 Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 20:51 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 1,583 | $2.97 | $4,701.51 |
DisclosureSEC source: 0000897069-26-000906 · form4.xml · nonDerivative · entry 1 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,693 Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 21:09 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 1,854 | $2.54 | $4,699.89 |
DisclosureSEC source: 0000897069-26-000745 · form4.xml · nonDerivative · entry 1 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,110 Read SEC document |
| January 01, 2026 Filed Feb 4, 2026 22:05 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionRestricted Stock Units · Derivative | 193 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-26-000220 · form4.xml · derivative · entry 3 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 193 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Distribution of vested restricted shares. F1 · derivative.expiration_date: Distribution of vested restricted shares. Read SEC document |
| January 01, 2026 Filed Feb 4, 2026 22:05 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock | 193 | $0.00 | $0.00 |
DisclosureSEC source: 0000897069-26-000220 · form4.xml · nonDerivative · entry 1 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,256 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Distribution of vested restricted shares. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:33 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantStock Options (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $0.20 | $0.00 |
DisclosureSEC source: 0000897069-25-001553 · form4.xml · derivative · entry 2 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires not disclosed F2 · derivative.exercise_date: Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years. F2 · derivative.expiration_date: Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:33 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 50,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-25-001553 · form4.xml · derivative · entry 1 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on October 1, 2026, and one-thirty-sixth each month thereafter until fully vested on October 1, 2028. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on October 1, 2026, and one-thirty-sixth each month thereafter until fully vested on October 1, 2028. Read SEC document |
| July 24, 2025 Filed Jul 28, 2025 20:36 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 1,366,046 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-25-001223 · form4.xml · derivative · entry 1 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,376,478 Underlying: Common Stock · 1,366,046 shares Expires not disclosed F1 · shares: Restricted stock granted under the Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan ("Omnibus Plan"), of which 1,349,245 shares are subject to stockholder approval of the revised Omnibus Plan. F2 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2026, and one-thirty-sixth each month thereafter until fully vested on January 1, 2028. F2 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2026, and one-thirty-sixth each month thereafter until fully vested on January 1, 2028. Read SEC document |
| April 01, 2025 Filed Apr 11, 2025 21:20 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock | 14,482 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000897069-25-000791 · form4.xml · nonDerivative · entry 1 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,339 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Distribution of vested restricted shares. Read SEC document |
| July 10, 2024 Filed Aug 2, 2024 21:12 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Tax withholdingCommon Stock | 220 | $1.71 | $376.20 |
DisclosureSEC source: 0000897069-24-001608 · form4.xml · nonDerivative · entry 4 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,857 Read SEC document |
| July 10, 2024 Filed Aug 2, 2024 21:12 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock | 644 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000897069-24-001608 · form4.xml · nonDerivative · entry 3 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,077 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Distribution of vested restricted shares. Read SEC document |
| June 28, 2024 Filed Aug 2, 2024 21:12 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 339 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-001608 · form4.xml · derivative · entry 9 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,914 Underlying: Common Stock · 339 shares Expires not disclosed F4 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals. F4 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals. Read SEC document |
| June 28, 2024 Filed Aug 2, 2024 21:12 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 339 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-001608 · form4.xml · derivative · entry 8 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,575 Underlying: Common Stock · 339 shares Expires not disclosed F4 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals. F4 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals. Read SEC document |
| June 28, 2024 Filed Aug 2, 2024 21:12 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 2,035 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-001608 · form4.xml · derivative · entry 7 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,236 Underlying: Common Stock · 2,035 shares Expires not disclosed F3 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2025, and one-thirty-sixth each month thereafter until fully vested on January 1, 2027. F3 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2025, and one-thirty-sixth each month thereafter until fully vested on January 1, 2027. Read SEC document |
| June 28, 2024 Filed Aug 2, 2024 21:12 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 2,713 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-001608 · form4.xml · derivative · entry 6 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,201 Underlying: Common Stock · 2,713 shares Expires not disclosed F2 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on January 1, 2025. F2 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on January 1, 2025. Read SEC document |
| April 05, 2024 Filed Aug 2, 2024 21:12 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Tax withholdingCommon Stock | 368 | $2.79 | $1,026.72 |
DisclosureSEC source: 0000897069-24-001608 · form4.xml · nonDerivative · entry 2 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,433 Read SEC document |
| April 05, 2024 Filed Aug 2, 2024 21:12 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock | 1,675 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000897069-24-001608 · form4.xml · nonDerivative · entry 1 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Distribution of vested restricted shares. Read SEC document |
| January 01, 2024 Filed Apr 12, 2024 20:50 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionRestricted Stock Units · Derivative | 1,675 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-000917 · form4.xml · derivative · entry 4 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,132 Underlying: Common Stock · 1,675 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Distribution of vested restricted shares. F1 · derivative.expiration_date: Distribution of vested restricted shares. F2 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| January 01, 2024 Filed Apr 12, 2024 20:50 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Tax withholdingCommon Stock | 368 | $2.79 | $1,026.72 |
DisclosureSEC source: 0000897069-24-000917 · form4.xml · nonDerivative · entry 2 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,433 F2 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| January 01, 2024 Filed Apr 12, 2024 20:50 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock | 1,675 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000897069-24-000917 · form4.xml · nonDerivative · entry 1 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Distribution of vested restricted shares. F2 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| October 12, 2023 Filed Oct 12, 2023 22:07 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantCommon Stock | 14,771 | $0.34 | $5,022.14 |
DisclosureSEC source: 0000897069-23-001470 · form4.xml · nonDerivative · entry 1 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,517 Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 22:47 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 40,690 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-000328 · doc1.xml · derivative · entry 3 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 440,328 Underlying: Common Stock · 40,690 shares Expires not disclosed F3 · derivative.exercise_date: Each restricted stock units represents a contingent right to receive one share of the tssuers common stock, following its vesting of one-third on 01/01/24; 01/01/25 and 01/01/26, upon the earlier of termination of employment; the third anniversary of the award date; a change in control, or the reporting persons death. F3 · derivative.expiration_date: Each restricted stock units represents a contingent right to receive one share of the tssuers common stock, following its vesting of one-third on 01/01/24; 01/01/25 and 01/01/26, upon the earlier of termination of employment; the third anniversary of the award date; a change in control, or the reporting persons death. Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 22:47 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 55,107 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-000328 · doc1.xml · derivative · entry 2 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,638 Underlying: Common Stock · 55,107 shares Expires not disclosed F2 · derivative.exercise_date: Each restricted stock units represents a contingent right to receive one share of the Issuers common stock, following its vesting on 01/01/24, upon the earlier of termination of employment; the third anniversary of the award date; a change in control, or the reporting persons death. F2 · derivative.expiration_date: Each restricted stock units represents a contingent right to receive one share of the Issuers common stock, following its vesting on 01/01/24, upon the earlier of termination of employment; the third anniversary of the award date; a change in control, or the reporting persons death. Read SEC document |
| December 31, 2022 Filed Jan 4, 2023 22:47 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 10,851 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-000328 · doc1.xml · derivative · entry 1 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,531 Underlying: Common Stock · 10,851 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. These restricted stock units are fully vested on date of grant. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. These restricted stock units are fully vested on date of grant. Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 20:57 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 10,850 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-018060 · doc1.xml · derivative · entry 1 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,680 Underlying: Common Stock · 10,850 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 20:23 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock | 7,601 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-015302 · doc1.xml · nonDerivative · entry 1 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,528 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Vesting of time-based restricted shares. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 21:42 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 20,064 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-013686 · doc1.xml · derivative · entry 1 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,830 Underlying: Common Stock · 20,064 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
| April 01, 2022 Filed Apr 11, 2022 21:49 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 247,841 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-008361 · doc1.xml · derivative · entry 1 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,766 Underlying: Common Stock · 247,841 shares Expires not disclosed F1 · derivative.exercise_date: Restricted Stock Units (RSUs) vest upon achievement of certain performance goals. The grant of 136,632 RSUs are subject to shareholder approval of the Issuer's 2019 Omnibus Incentive Plan (the "Plan") to increase the authorized shares under the Plan. F1 · derivative.expiration_date: Restricted Stock Units (RSUs) vest upon achievement of certain performance goals. The grant of 136,632 RSUs are subject to shareholder approval of the Issuer's 2019 Omnibus Incentive Plan (the "Plan") to increase the authorized shares under the Plan. F2 · balance_after: The previous filing understated this number. This new total accurately reflects the cumulative total of Restricted Stock Units for the reporting person. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 21:53 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 10,715 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-008003 · doc1.xml · derivative · entry 2 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,781 Underlying: Common Stock · 10,715 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 22:30 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 6,722 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-000300 · doc1.xml · derivative · entry 1 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,722 Underlying: Common Stock · 6,722 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
| December 31, 2021 Filed Jan 6, 2022 22:25 UTC Amendment | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 6,722 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-000775 · doc1.xml · derivative · entry 1 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,780 Underlying: Common Stock · 6,722 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F2 · balance_after: This Amendment is being filed to correct the balance in Box 9 - this should have reflected a cumulative balance. Read SEC document |
| November 01, 2021 Filed Apr 4, 2022 21:53 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 4,286 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-008003 · doc1.xml · derivative · entry 1 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,066 Underlying: Common Stock · 4,286 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 20:54 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 6,024 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-017837 · doc1.xml · derivative · entry 1 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,024 Underlying: Common Stock · 6,024 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
| September 30, 2021 Filed Jan 6, 2022 21:00 UTC Amendment | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 6,024 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-000712 · doc1.xml · derivative · entry 1 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,058 Underlying: Common Stock · 6,024 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F2 · balance_after: This Amendment is being filed to correct the balance in Box 9 - this should have reflected a cumulative balance. Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 20:42 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Tax withholdingCommon Stock | 2,254 | $6.20 | $13,974.80 |
DisclosureSEC source: 0001567619-21-014753 · doc1.xml · nonDerivative · entry 2 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,927 Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 20:42 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantCommon Stock | 7,601 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-014753 · doc1.xml · nonDerivative · entry 1 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,181 F1 · price: Vesting of time-based restricted shares. Read SEC document |
| August 05, 2021 Filed Aug 9, 2022 20:23 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Tax withholdingCommon Stock | 1,782 | $3.17 | $5,648.94 |
DisclosureSEC source: 0001567619-22-015302 · doc1.xml · nonDerivative · entry 2 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,746 Read SEC document |
| July 08, 2021 Filed Jul 9, 2021 20:34 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 1,907 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-013187 · doc1.xml · derivative · entry 3 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,034 Underlying: Common Stock · 10,034 shares Expires not disclosed F3 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F3 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
| July 08, 2021 Filed Jul 9, 2021 20:34 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 12,858 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-013187 · doc1.xml · derivative · entry 2 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,858 Underlying: Common Stock · 12,858 shares Expires not disclosed F2 · derivative.exercise_date: The Restricted Stock Units vest upon achievement of certain performance goals. F2 · derivative.expiration_date: The Restricted Stock Units vest upon achievement of certain performance goals. Read SEC document |
| July 08, 2021 Filed Jul 9, 2021 20:34 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 8,572 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-013187 · doc1.xml · derivative · entry 1 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,572 Underlying: Common Stock · 8,572 shares Expires not disclosed F1 · derivative.exercise_date: The restricted stock units vest in two equal installments beginning July 1, 2022. F1 · derivative.expiration_date: The restricted stock units vest in two equal installments beginning July 1, 2022. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 21:14 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 8,127 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-011989 · doc1.xml · derivative · entry 1 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,127 Underlying: Common Stock · 8,127 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.